Abstract:Background & aims: Management of long-term immunosuppression following liver transplantation (LT) remains empirical. Surveillance liver biopsies in combination with transcriptional profiling could overcome this challenge by identifying recipients with active alloimmune-mediated liver damage despite normal liver tests, but this approach lacks applicability. Our aim was to investigate the utility of non-invasive tools for the stratification of stable long-term survivors of LT, according to their immunological risk and need for immunosuppression. Methods: We conducted a cross-sectional multicentre study of 190 adult LT recipients assessed to determine their eligibility to participate in an immunosuppression withdrawal trial. Patients had stable liver allograft function and had been transplanted for non-autoimmune non-replicative viral liver disease >3 years before inclusion. We performed histological, immunogenetic and serological studies and measured the intrahepatic transcript levels of an 11-gene classifier highly specific for T cell-mediated rejection (TCMR). Results: In this cohort, 35.8% of patients harboured clinically silent fibro-inflammatory liver lesions (13.7% had mild damage and 22.1% had moderate-to-severe damage). The severity of liver allograft damage was positively associated with TCMR-related transcripts, class II donor-specific antibodies (DSAs), ALT, AST, and liver stiffness measurement (LSM), and negatively correlated with serum creatinine and tacrolimus trough levels. Liver biopsies were stratified according to their TCMR transcript levels using a cut-off derived from biopsies with clinically significant TCMR. Two multivariable prediction models, integrating ALT+LSM or ALT+class II DSAs, had a high discriminative capacity for classifying patients with or without alloimmune damage. The latter model performed well in an independent cohort of 156 liver biopsies obtained from paediatric liver recipients with similar inclusion/exclusion criteria. Conclusion: ALT, class II DSAs and LSM are valuable tools to non-invasively identify stable LT recipients without significant underlying alloimmunity who could benefit from minimisation of immunosuppression. Lay summary: A large proportion of liver transplant patients with normal liver tests have inflammatory liver lesions, which in 17% of cases are molecularly indistinguishable from those seen at the time of rejection. ALT, class II donor-specific antibodies and liver stiffness are useful in identifying patients with this form of subclinical rejection. We propose these markers as a useful tool to help clinicians determine if the immunosuppression administered is adequate.

Serum and tissue biomarkers of plasma cell-rich rejection in liver transplant recipients

Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation

CLINICOPATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF PLASMA CELL RICH REJECTION IN RENAL TRANSPLANT BIOPSIES

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Serum proteomic predicts effectiveness and reveals potential biomarkers for complications in liver transplant patients.

Non-invasive alloimmune risk stratification of long-term liver transplant recipients

Plasma Microrna, A Potential Biomarker for Acute Rejection after Liver Transplantation

Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up

Incidence and risk factors for chronic rejection in pediatric liver transplantation

Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation.

The Immunological Basis of Liver Allograft Rejection

The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection

Rejection markers in kidney transplantation: do new technologies help children?

S1871 To Biopsy or Not to Biopsy: A Cochrane Diagnostic Meta-Analysis of Non-Invasive Biomarkers for Acute T-Cell Mediated Liver Transplant Rejection

Diagnosing Acute Cellular Rejection after Paediatric Liver Transplantation-Is There Room for Interleukin Profiles?

Predicting Cellular Rejection of Renal Allograft Based on the Serum Proteomic Fingerprint

Clinical Analysis and Proteomic Screening Biomarkers for Graft-Versus-Host Disease After Liver Transplant

Monitoring the operationally tolerant liver allograft recipient

Renal graft function in transplanted patients correlates with CD45RC T cell phenotypic signature

Tissue Expression of Programmed Cell Death 1 Ligand1 (PD-L1) in Biopsies of Transplant Livers of Pediatric Patients as a Possible Marker of Acute Cellular Rejection

miRNA as potential biomarkers after liver transplantation: A systematic review